SuperworthEnveric Biosciences revenue ENVB
Sales by quarter and over the last twelve months, from 2014.
- Last 12 months, to Sep 30, 2020
- $35.4M
- Latest quarter, Q3 FY20
- $8.5M
- −7% on a year earlier
- Fiscal year 2019
- $39.9M
- −7% on the year before
Enveric Biosciences' revenue was $35.4M over the twelve months to Sep 30, 2020, down 14% on a year earlier.
In its latest quarter, Q3 FY20, it was $8.5M, down 7% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2019 | $39.9M | −7% |
| FY2018 | $43M | −12% |
| FY2017 | $48.6M | +34% |
| FY2016 | $36.1M | +78% |
| FY2015 | $20.3M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY20 | $8.5M | −7% | $35.4M | |
| Q2 FY20 | $8.3M | −25% | $36.1M | |
| Q1 FY20 | $9.6M | −10% | $38.8M | |
| Q4 FY19 | $9.1M | −12% | $39.9M | |
| Q3 FY19 | $9.1M | −13% | $41.1M | |
| Q2 FY19 | $11M | −1% | $42.6M | |
| Q1 FY19 | $10.7M | −3% | $42.6M | |
| Q4 FY18 | $10.3M | −10% | $43M | |
| Q3 FY18 | $10.6M | −16% | $44.2M | |
| Q2 FY18 | $11.1M | −10% | $46.1M | |
| Q1 FY18 | $11.1M | −10% | $47.3M | |
| Q4 FY17 | $11.5M | −8% | $48.6M |
Against its peers
Companies in Healthcare nearest Enveric Biosciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ENVBEnveric Biosciences | n/m | |
| NEPHNephros | $20.7M | +24% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| APTAlpha Pro Tech | $61.9M | +6% a year |
| Peer median | $41.3M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Enveric Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.